TBK1 and metabolic dysfunction-associated steatotic liver disease: Corresponding to it, TBK1 inhibitors can alleviate PA-mediated lipid accumulation, inflammatory reaction and adipocyte apoptosis in hepatocytes (Zhou et al., 2020b), indicating the vital indicative significance of TBK1 in the progression of NAFLD.